Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for a variety of malignant and non-malignant hematological and congenital diseases. Approximately 40-50% of all HSCTs are performed across the ABO blood group barrier. Both immediate and delayed hemolytic complications can occur in these instances. This lecture will cover the concepts of ABO mismatch HSCT, the ways we mitigate the complications in collection and manufacturing the product and ways to provide extended support to these patients in the blood bank setting.
Dr. Daniela Hermelin is originally from South Florida. She graduated from Brandeis University in Boston with a combined degree in music and biology. After medical school at St. George’s University, she started a nutritional and wellness program called Wellness to Be, M.D., which she ran for five years while raising her growing family and before starting our residency program in in 2014. Although her original excitement to pursue pathology was for the anatomic pathology, she was exposed to Blood Banking and Apheresis therapy during her first year and “fell in love”. She is passionate about Transfusion Medicine with particular interests in thrombotic microangiopathies, building integrative clinical pathology consultations, and as a clinician-teacher using social media to expand and transform medical education. She is, a member of the AABB eLearning Committee, a member of the Social Media Transfusion Journal Working Group and a Board Member of the Heart of American Blood Bank Association. Dr. Hermelin will join the faculty of St. Louis University Hospital as an Associate Medical Director of Transfusion Medicine and Medical Director of Apheresis Therapies this July.
When not engaged in pathology, Dr. Hermelin keeps busy at home with her husband raising their six children, who ages range from four through thirteen years.
